Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors

Por Fecher, Leslie A, Sharfman, William H
Publicado no Biologics (2015)

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

Por Fecher, Leslie A., Agarwala, Sanjiv S., Hodi, F. Stephen, Weber, Jeffrey S.
Publicado em 2013

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy

Por Rizzo, Jason M., Fecher, Leslie A., Chan, May P., Durham, Alison B.
Publicado no JAAD Case Rep (2018)

Metastatic Merkel cell carcinoma response to nivolumab

Por Walocko, Frances M., Scheier, Benjamin Y., Harms, Paul W., Fecher, Leslie A., Lao, Christopher D.
Publicado no J Immunother Cancer (2016)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab

Por Walocko, Frances M., Scheier, Benjamin Y., Harms, Paul W., Fecher, Leslie A., Lao, Christopher D.
Publicado no J Immunother Cancer (2017)

An adolescent with uveal melanoma and BAP1 tumor predisposition syndrome

Por Young, Kelly Z., Fossum, Sara L., Lowe, Lori, Else, Tobias, Fecher, Leslie A., Demirci, Hakan, Cha, Kelly B.
Publicado no JAAD Case Rep (2020)

Acute visual loss after ipilimumab treatment for metastatic melanoma

Por Wilson, Melissa A., Guld, Kelly, Galetta, Steven, Walsh, Ryan D., Kharlip, Julia, Tamhankar, Madhura, McGettigan, Suzanne, Schuchter, Lynn M., Fecher, Leslie A.
Publicado no J Immunother Cancer (2016)

Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

Por Chu, Emily Y., Wanat, Karolyn A., Miller, Christopher J., Amaravadi, Ravi K., Fecher, Leslie A., Brose, Marcia S., McGettigan, Suzanne, Giles, Lydia R., Schuchter, Lynn M., Seykora, John T., Rosenbach, Misha
Publicado no J Am Acad Dermatol (2012)

Collapse of the CD27+ B cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers

Por Carpenter, Erica L., Mick, Rosemarie, Rech, Andrew J., Beatty, Gregory L., Colligon, Theresa A., Rosenfeld, Myrna R., Kaplan, David E., Chang, Kyong-Mi, Domchek, Susan M., Kanetsky, Peter A., Fecher, Leslie A., Flaherty, Keith T., Schuchter, Lynn M., Vonderheide, Robert H.
Publicado em 2009

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Por Lin, Heng, Wei, Shuang, Hurt, Elaine M., Green, Michael D., Zhao, Lili, Vatan, Linda, Szeliga, Wojciech, Herbst, Ronald, Harms, Paul W., Fecher, Leslie A., Vats, Pankaj, Chinnaiyan, Arul M., Lao, Christopher D., Lawrence, Theodore S., Wicha, Max, Hamanishi, Junzo, Mandai, Masaki, Kryczek, Ilona, Zou, Weiping
Publicado no J Clin Invest (2018)

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Por Lin, Heng, Wei, Shuang, Hurt, Elaine M., Green, Michael D., Zhao, Lili, Vatan, Linda, Szeliga, Wojciech, Herbst, Ronald, Harms, Paul W., Fecher, Leslie A., Vats, Pankaj, Chinnaiyan, Arul M., Lao, Christopher D., Lawrence, Theodore S., Wicha, Max, Hamanishi, Junzo, Mandai, Masaki, Kryczek, Ilona, Zou, Weiping
Publicado no J Clin Invest (2018)

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

Por Kim, Kevin B., Kefford, Richard, Pavlick, Anna C., Infante, Jeffrey R., Ribas, Antoni, Sosman, Jeffrey A., Fecher, Leslie A., Millward, Michael, McArthur, Grant A., Hwu, Patrick, Gonzalez, Rene, Ott, Patrick A., Long, Georgina V., Gardner, Olivia S., Ouellet, Daniele, Xu, Yanmei, DeMarini, Douglas J., Le, Ngocdiep T., Patel, Kiran, Lewis, Karl D.
Publicado no J Clin Oncol (2013)

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Por Rangwala, Reshma, Leone, Robert, Chang, Yunyoung C, Fecher, Leslie A, Schuchter, Lynn M, Kramer, Amy, Tan, Kay-See, Heitjan, Daniel F, Rodgers, Glenda, Gallagher, Maryann, Piao, Shengfu, Troxel, Andrea B, Evans, Tracey L, DeMichele, Angela M, Nathanson, Katherine L, O’Dwyer, Peter J, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, Amaravadi, Ravi K
Publicado em 2014

Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

Por Rangwala, Reshma, Chang, Yunyoung C, Hu, Janice, Algazy, Kenneth M, Evans, Tracey L, Fecher, Leslie A, Schuchter, Lynn M, Torigian, Drew A, Panosian, Jeffrey T, Troxel, Andrea B, Tan, Kay-See, Heitjan, Daniel F, DeMichele, Angela M, Vaughn, David J, Redlinger, Maryann, Alavi, Abass, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, O’Dwyer, Peter J, Amaravadi, Ravi K
Publicado em 2014

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

Por Falchook, Gerald S, Lewis, Karl D, Infante, Jeffrey R, Gordon, Michael S, Vogelzang, Nicholas J, DeMarini, Douglas J, Sun, Peng, Moy, Christopher, Szabo, Stephen A., Roadcap, Lori T, Peddareddigari, Vijay G R, Lebowitz, Peter F, Le, Ngocdiep T, Burris, Howard A, Messersmith, Wells A, O'Dwyer, Peter J, Kim, Kevin B., Flaherty, Keith, Bendell, Johanna C., Gonzalez, Rene, Kurzrock, Razelle, Fecher, Leslie A
Publicado em 2012

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Por Rivera, Donna R., Peters, Solange, Panagiotou, Orestis A., Shah, Dimpy P., Kuderer, Nicole M., Hsu, Chih-Yuan, Rubinstein, Samuel M., Lee, Brendan J., Choueiri, Toni K., de Lima Lopes, Gilberto, Grivas, Petros, Painter, Corrie A., Rini, Brian I., Thompson, Michael A., Arcobello, Jonathan, Bakouny, Ziad, Doroshow, Deborah B., Egan, Pamela C., Farmakiotis, Dimitrios, Fecher, Leslie A., Friese, Christopher R., Galsky, Matthew D., Goel, Sanjay, Gupta, Shilpa, Halfdanarson, Thorvardur R., Halmos, Balazs, Hawley, Jessica E., Khaki, Ali Raza, Lemmon, Christopher A., Mishra, Sanjay, Olszewski, Adam J., Pennell, Nathan A., Puc, Matthew M., Revankar, Sanjay G., Schapira, Lidia, Schmidt, Andrew, Schwartz, Gary K., Shah, Sumit A., Wu, Julie T., Xie, Zhuoer, Yeh, Albert C., Zhu, Huili, Shyr, Yu, Lyman, Gary H., Warner, Jeremy L.
Publicado no Cancer Discov (2020)

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Por Bettegowda, Chetan, Sausen, Mark, Leary, Rebecca J., Kinde, Isaac, Wang, Yuxuan, Agrawal, Nishant, Bartlett, Bjarne R., Wang, Hao, Luber, Brandon, Alani, Rhoda M., Antonarakis, Emmanuel S., Azad, Nilofer S., Bardelli, Alberto, Brem, Henry, Cameron, John L., Lee, Clarence C., Fecher, Leslie A., Gallia, Gary L., Gibbs, Peter, Le, Dung, Giuntoli, Robert L., Goggins, Michael, Hogarty, Michael D., Holdhoff, Matthias, Hong, Seung-Mo, Jiao, Yuchen, Juhl, Hartmut H., Kim, Jenny J., Siravegna, Giulia, Laheru, Daniel A., Lauricella, Calogero, Lim, Michael, Lipson, Evan J., Marie, Suely Kazue Nagahashi, Netto, George J., Oliner, Kelly S., Olivi, Alessandro, Olsson, Louise, Riggins, Gregory J., Sartore-Bianchi, Andrea, Schmidt, Kerstin, Shih, le-Ming, Oba-Shinjo, Sueli Mieko, Siena, Salvatore, Theodorescu, Dan, Tie, Jeanne, Harkins, Timothy T., Veronese, Silvio, Wang, Tian-Li, Weingart, Jon D., Wolfgang, Christopher L., Wood, Laura D., Xing, Dongmei, Hruban, Ralph H., Wu, Jian, Allen, Peter J., Schmidt, C. Max, Choti, Michael A., Velculescu, Victor E., Kinzler, Kenneth W., Vogelstein, Bert, Papadopoulos, Nickolas, Diaz, Luis A.
Publicado em 2014